EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines

European Journal of Cancer Care

Volumn 20, Issue 1, 2011, Pages 106-112

  Zhang, Y B ^a   Niu, H T ^b   Chang, J W ^c   Dong, G L ^d   Ma, X B ^a  

^a NORTH CHINA COAL MEDICAL COLLEGE   (China)

^b QINGDAO UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d Tangshan People Hospital   (China)

Author keywords

Bladder cancer; EZH2; Proliferation; RNA interference

Indexed keywords

DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; MESSENGER RNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

AGED; ARTICLE; BLADDER TUMOR; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; G1 PHASE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 78650311634     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01148.x     Document Type: Article

References (23)

1. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P. & Akslen L.A. (2006) Ezh2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology 24, 268-273.
2. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E. & Helin K. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. The EMBO Journal 22, 5323-5335.
3. Bryant R.J., Cross N.A., Eaton C.L., Hamdy F.C. & Cunliffe V.T. (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. The Prostate 67, 547-556.
4. Campbell M.F., Walsh P.C. & Retik A.B. (2002) Campbell's Urology, 8th edn. Saunders, Philadelphia, PA, USA; p.4v (xl, 3954, 128p).
5. Cardoso C., Mignon C., Hetet G., Grandchamps B., Fontes M. & Colleaux L. (2000) The human EZH2 gene: genomic organization and revised mapping in 7q35 within the critical region for malignant myeloid disorders. European Journal of Human Genetics 8, 174-180.
6. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., Aas T., Otte A.P. & Akslen L.A. (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research 12, 1168-1174.
7. Francis N.J. & Kingston R.E. (2001) Mechanisms of transcriptional memory. Nature Reviews. Molecular Cell Biology 2, 409-421.
8. Gil J., Bernard D. & Peters G. (2005) Role of polycomb group proteins in stem cell self-renewal and cancer. DNA and Cell Biology 24, 117-125.
9. Hannon G.J. (2002) RNA interference. Nature 418, 244-251.
10. Helpap B. & Kollermann J. (2000) Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of the urothelial tumors of the urinary bladder. Human Pathology 31, 745-750.
11. Hinz S., Kempkensteffen C., Weikert S., Schostak M., Schrader M., Miller K. & Christoph F. (2007) EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. Tumour Biology 28, 151-157.
12. Jacobs J.J. & van Lohuizen M. (1999) Cellularm emory of transcriptional states by Polycomb-group proteins. Seminars in Cell and Developmental Biology 10, 227-235.
13. Jemal A., Siegel R., Ward E., Murray T., Xu J. & Thun M.J. (2007) Cancer statistics. CA: A Cancer Journal for Clinicians 57, 43-66.
14. Kirmizis A., Bartley S.M., Kuzmichev A., Margueron R., Reinberg D., Green R. & Farnham P.J. (2004) Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes and Development 18, 1592-1605.
15. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A. & Chinnaiyan A.M. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100, 11606-11611.
16. Murphy W.M., Takezawa K. & Maruniak N.A. (2002) Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. The Journal of Urology 168, 968-972.
17. O'Caroll D., Erhardt S., Pagani M., Barton S.C., Surani M.A. & Jenuwein T. (2001) The polycomb group gene Ezh2 is required for early mouse development. Molecular and Cellular Biology 21, 4330-4336.
18. Pectasides D., Pectasides M. & Nikolaou M. (2005) Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. European Urology 48, 60-68; [PubMed: 15967253].
19. Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., Packeisen J., Sewalt R.A., Otte A.P. & van Diest P.J. (2003) Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5, 481-488.
20. Samaratunqa H., Makarov D.V. & Epstein J.I. (2002) Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 60, 315-319.
21. Sasaki M., Yamaguchi J., Itatsu K., Ikeda H. & Nakanuma Y. (2008) Over-expression of polycomb group protein EZH2 relates to decreased expression of p16INK4a in cholangiocarcinogenesis in hepatolithiasis. The Journal of Pathology 215, 175-183.
22. Sudo T., Utsunomiya T., Mimori K., Nagahara H., Ogawa K., Inoue H., Wakiyama S., Fujita H., Shirouzu K. & Mori M. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. British Journal of Cancer 92, 1754-1758.
23. Van Lohuizen M. (1999) The trithorax-group and polycombgroup chromatin modifiers: implications for disease. Current Opinion in Genetics and Development 9, 355-361.